Elastography Analysis Report
AI-Powered Liver Fibrosis & Steatosis Assessment
Report ID: SAMPLE-2025-001
Generated: June 11, 2025
Language: English
Patient Information
| Name | Age | Sex | Weight | Height | BMI |
|---|---|---|---|---|---|
| John Doe (Sample) | 45 | Male | 82 kg | 170 cm | 28.5 |
Elastography & Liver Scores
| LIVER STIFFNESS | 7.2 kPa |
| Machine | FibroScan 630 Expert |
| Stage | F0-F1 |
| STEATOSIS | 285 dB/m |
| Grade | S2 |
| Score | Value | Interpretation |
|---|---|---|
| FIBROAI COMPOSITE | 0.25 | Low risk (0.00-0.40 Low, 0.41-0.70 Moderate, >0.70 High) |
| APRI | 0.32 | Low probability (<0.5 Low, 0.5-1.5 Int, >1.5 High) |
| FIB-4 | 1.12 | Low probability (<1.3 Low, 1.3-2.67 Int, >2.67 High) |
| NAFLD FS | -0.85 | Intermediate probability (<-1.455 Low, -1.455-0.676 Int, >0.676 High) |
| Agile 3+ | 0.52 | Intermediate probability (<0.451 Low, 0.451-0.679 Int, >0.679 High) |
| Agile 4 | 0.28 | Low probability (<0.35 Low, 0.35-0.67 Int, >0.67 High) |
MAFLD/NAFLD Assessment
Assessment
Findings fulfill criteria for MAFLD (Metabolic dysfunction-associated fatty liver disease).
Steatosis severity: Moderate (S2).
Metabolic criteria: Overweight/obesity, Type 2 diabetes.
No evidence of dual etiology.
Clinical Interpretation & Recommendations
Clinical Interpretation
Elastography demonstrates F0-F1 fibrosis (7.2 kPa) and S2 steatosis (285 dB/m) using FibroScan 630 Expert reference ranges.
FibroAI Composite Score 0.25 indicates low risk for advanced fibrosis.
Findings fulfill criteria for MAFLD.
Moderate hepatic steatosis is present and should be interpreted in the context of metabolic risk factors.
Advice / Recommendations
- Lifestyle counseling advised. Routine follow-up per current guidelines.
- Optimize metabolic risk factors and weight management.
- Consider hepatology consultation if risk factors persist.
References
- FibroAI Composite Score: Proprietary algorithm v0.9 (validation pending)
- MAFLD Criteria: Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease. J Hepatol 2020;73:202-9
- Elastography Guidelines: EASL Clinical Practice Guidelines. J Hepatol 2015;63:237-64
Medical References
- Castera L, et al. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-64.
- Ferraioli G, et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography. Ultrasound Med Biol. 2015;41(5):1161-79.
- Wong VW, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454-62.
🚨 SAMPLE REPORT NOTICE
This is a demonstration report with sample data for preview purposes only. Real patient reports require authenticated professional access and contain actual medical analysis.
Generated by FibroAI - Advanced AI-Powered Elastography Analysis
For support: [email protected]